Effect of Tumor Location on Outcome After Laparoscopic Low Rectal Cancer Surgery: A Propensity Score Matching Analysis
- PMID: 35394940
- DOI: 10.1097/DCR.0000000000001965
Effect of Tumor Location on Outcome After Laparoscopic Low Rectal Cancer Surgery: A Propensity Score Matching Analysis
Abstract
Background: Dissection of the distal anterolateral aspect of the mesorectum remains a surgical challenge for low rectal cancer, posing a higher risk of residual mesorectum, which might lead to the increased incidence of local recurrence for patients with anterior wall involvement.
Objective: This study aimed to assess the effect of tumor location on outcome after laparoscopic low rectal cancer surgery.
Design: This is a single-center, retrospective study.
Settings: The study was conducted at West China Hospital in China.
Patients: Patients with low rectal cancer who underwent laparoscopic total mesorectal excision from 2011 to 2016 were enrolled. Patients were divided into anterior and nonanterior groups according to tumor location. Propensity score matching analysis was used to reduce the selection bias.
Main outcome measures: The primary end point was local recurrence. The secondary end points included overall survival, disease-free survival, and the positive rate of circumferential resection margin.
Results: A total of 404 patients were included, and 176 pairs were generated by propensity score matching analysis. Multivariate analysis showed that anterior location was an independent risk factor of local recurrence (HR, 12.6; p = 0.006), overall survival (HR, 3.0; p < 0.001), and disease-free survival (HR, 2.3; p = 0.001). For patients with clinical stage II/III or T3/4, anterior location remained a prognostic factor for higher local recurrence and poorer survival. Local recurrence was rare in patients with clinical stage II/III (1.4%) or T3/4 (1.5%) tumors that were not located anteriorly.
Limitations: This study was limited by its retrospective nature.
Conclusions: Anterior location is an independent risk factor of local recurrence, overall survival, and disease-free survival for low rectal cancer. More strict and selective use of neoadjuvant therapy should be considered for patients who have clinical stage II/III or T3/4 tumors that are not located anteriorly. A larger cohort study is warranted to validate the prognostic role of anterior location for low rectal cancer. See Video Abstract at http://links.lww.com/DCR/B622.
Impacto de la localizacin del tumor en el resultado posterior a ciruga laparoscpica de cncer de recto inferior un puntaje de propensin por anlisis de concordancia: ANTECEDENTES:La disección de la cara anterolateral distal del mesorrecto sigue siendo un desafío quirúrgico en el cáncer de recto inferior, constituyendo un alto riesgo de mesorrecto residual, que podría ocasionar una mayor incidencia de recurrencia local en pacientes con compromiso de la pared anterior.OBJETIVO:El objetivo del estudio fue evaluar el efecto de la localización del tumor en el resultado posterior a la cirugía laparoscópica de cáncer de recto inferior.DISEÑO:Estudio restrospectivo de un único centro.ÁMBITO:El estudio se realizó en el West China Hospital en China.PACIENTES:Pacientes con cáncer de recto inferior que se sometieron a excisión mesorrectal total laparoscópica entre 2011 y 2016. Los pacientes se dividieron en grupos, anterior y no anterior, según la localización del tumor. Se utilizó un puntaje de propensión por análisis de concordancia para reducir el sesgo de selección.PRINCIPALES VARIABLES EVALUADAS:El objetivo principal fue la recurrencia local. Los objetivos secundarios incluyeron la sobrevida global, la sobrevida libre de enfermedad y la tasa de positividad del margen de resección circunferencial.RESULTADOS:Se incluyeron un total de 404 pacientes y se generaron 176 pares mediante un puntaje de propensión por análisis de concordancia. El análisis multivariado mostró que la localización anterior era un factor de riesgo independiente de recidiva local (HR = 12,6, p = 0,006), sobrevida global (HR = 3,0, p <0,001) y sobrevida libre de enfermedad (HR = 2,3, p = 0,001). En pacientes con estadio clínico II /III o T3/4, la ubicación anterior continuó como un factor pronóstico para una mayor recurrencia local y una menor sobrevida. La recidiva local fue excepcional en pacientes con tumores en estadio clínico II / III (1,4%) o T3 / 4 (1,5%) que no estaban localizados hacia anterior.LIMITACIONES:Este estudio estuvo limitado por su carácter retrospectivo.CONCLUSIONES:La localización anterior es un factor de riesgo independiente de recidiva local, sobrevida global y sobrevida libre de enfermedad para el cáncer de recto inferior. Se debe considerar un uso más estricto y selectivo de la terapia neoadyuvante para pacientes en estadio clínico II / III o T3 /4 de tumores que no se localizan hacia anterior. Se justifica un estudio de cohorte más grande para validar el impacto pronóstico de una ubicación anterior del cáncer de recto inferior. Consulte Video Resumen en http://links.lww.com/DCR/B622. (Traducción-Dr. Lisbeth Alarcon-Bernes).
Copyright © The ASCRS 2022.
Similar articles
-
Perioperative Blood Transfusions Are Associated With Worse Overall Survival But Not Disease-Free Survival After Curative Rectal Cancer Resection: A Propensity Score-Matched Analysis.Dis Colon Rectum. 2021 Aug 1;64(8):946-954. doi: 10.1097/DCR.0000000000002006. Dis Colon Rectum. 2021. PMID: 34214054 Free PMC article.
-
Prognostic Value of the Circumferential Resection Margin After Curative Surgery for Rectal Cancer: A Multicenter Propensity Score-Matched Analysis.Dis Colon Rectum. 2023 Jul 1;66(7):887-897. doi: 10.1097/DCR.0000000000002294. Epub 2022 Mar 29. Dis Colon Rectum. 2023. PMID: 35348529
-
Neoadjuvant Modified FOLFOXIRI With Selective Radiotherapy in Locally Advanced Rectal Cancer: Long-term Outcomes of Phase II Study and Propensity-Score-Matched Comparison With Chemoradiotherapy.Dis Colon Rectum. 2023 Jul 1;66(7):934-945. doi: 10.1097/DCR.0000000000002424. Epub 2022 Jul 12. Dis Colon Rectum. 2023. PMID: 35834598 Clinical Trial.
-
Neoadjuvant Therapy in Stage II/III Rectal Cancer: A Retrospective Study in a Disparate Population and the Effect on Survival.Dis Colon Rectum. 2021 Oct 1;64(10):1212-1221. doi: 10.1097/DCR.0000000000001977. Dis Colon Rectum. 2021. PMID: 34516443 Review.
-
Cost-Effectiveness Analysis: Selective Use of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.Dis Colon Rectum. 2023 Jul 1;66(7):946-956. doi: 10.1097/DCR.0000000000002673. Epub 2023 Jun 5. Dis Colon Rectum. 2023. PMID: 37311698 Review.
Cited by
-
A boundary-guided transformer for measuring distance from rectal tumor to anal verge on magnetic resonance images.Patterns (N Y). 2023 Mar 27;4(4):100711. doi: 10.1016/j.patter.2023.100711. eCollection 2023 Apr 14. Patterns (N Y). 2023. PMID: 37123445 Free PMC article.
-
Total neoadjuvant therapy for locally advanced rectal cancer: a three-group propensity score matched study.Int J Colorectal Dis. 2024 Mar 16;39(1):38. doi: 10.1007/s00384-024-04610-1. Int J Colorectal Dis. 2024. PMID: 38492080 Free PMC article.
-
Prognostic impact of tumor location after abdominoperineal resection of rectal cancer: A single-center propensity score matching analysis based on 1806 cases.Tech Coloproctol. 2025 Apr 9;29(1):99. doi: 10.1007/s10151-025-03114-6. Tech Coloproctol. 2025. PMID: 40205263 Free PMC article. Review.
-
A New Approach to Ultra-Low Anterior Resection-Intersphincteric Dissection With Total Hiatal Ligament Excision for Very Low Rectal Cancer Located in the Posterior Wall of the Rectum: A More Satisfactory Technique for Local Recurrence Control.Cancer Med. 2024 Oct;13(19):e70307. doi: 10.1002/cam4.70307. Cancer Med. 2024. PMID: 39387535 Free PMC article.
References
-
- Heald RJ. A new approach to rectal cancer. Br J Hosp Med. 1979;22:277–281.
-
- MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457–460.
-
- McCall JL, Cox MR, Wattchow DA. Analysis of local recurrence rates after surgery alone for rectal cancer. Int J Colorectal Dis. 1995;10:126–132.
-
- Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg. 1998;133:894–899.
-
- Carlsen E, Schlichting E, Guldvog I, Johnson E, Heald RJ. Effect of the introduction of total mesorectal excision for the treatment of rectal cancer. Br J Surg. 1998;85:526–529.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials